Precision Biosciences CLO Dario Scimeca Sells $27.5K of Stock
Dario Scimeca, CLO, sold 2,821 shares of Precision Biosciences Inc at $9.75 a share, worth $27.5K in total on Nov 10, 2026. Shares held after the trade: 56,782 (-4.7%).
Precision BioSciences provided an update on its previously announced public offering of 10,235,077 shares of common stock and 5,893,964 pre-funded warrants. The company expects the net proceeds to extend its cash runway into the fourth quarter of 2029, providing sufficient capital to fund its PBGENE-HBV and PBGENE-DMD clinical programs through key inflection points.
Precision BioSciences priced an underwritten public offering of approximately 10.2 million shares and 5.9 million pre-funded warrants for gross proceeds of $125 million. The offering included participation from several life sciences investors including First Light Asset Management and MPM BioImpact. Proceeds will fund research and development for PBGENE-HBV and PBGENE-DMD programs.
Precision BioSciences announced successful Phase 1 results for PBGENE-HBV in chronic hepatitis B, showing 100% pgRNA loss to undetectable levels at the 0.4 mg/kg dose and evidence of cccDNA elimination. The company also reported that the first patient dosed with PBGENE-DMD for Duchenne muscular dystrophy completed an eight-week safety observation period with no serious adverse events, allowing the Phase 1/2 trial to proceed with additional dosing.
Precision BioSciences reported Q3 2026 financial results, highlighting a cash position of $108 million which is expected to fund operations through 2028. The company advanced its clinical pipeline, including dosing the first patient in the Phase 1/2 FUNCTION-DMD study and preparing for a late-breaking oral presentation of PBGENE-HBV data at AASLD's The Liver Meeting.
“We entered 2026 with a clear plan to deliver multiple important clinical and operational milestones this year and we have made significant progress executing against that plan. In the third quarter, we continued to advance PBGENE-HBV in the ELIMINATE-B trial for chronic hepatitis B and are very excited about the opportunity to present important clinical data in a late-breaking oral presentation at the upcoming AASLD Liver Meeting on November 8th at 2:15pm MST.”
Michael Amoroso, Chief Executive Officer of Precision BioSciences
“The third quarter also marked an important milestone for Precision BioSciences and more importantly for the children who live with Duchenne muscular dystrophy (DMD). Our team alongside our investigators commenced dosing of the first patient in the FUNCTION-DMD trial.”
Michael Amoroso, Chief Executive Officer of Precision BioSciences
Precision BioSciences is a clinical-stage gene editing company focused on its ARCUS technology. As of October 29, 2026, the company had 27,935,719 shares of common stock outstanding and continues to report significant operating losses with a need for substantial additional funding to support its research and development programs.